A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer

Castration Resistant ◽

Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)

BMC Cancer ◽

10.1186/s12885-019-5526-3 ◽

2019 ◽

Vol 19 (1) ◽

Cited By ~ 4

Author(s):

Taro Iguchi ◽

Satoshi Tamada ◽

Minoru Kato ◽

Sayaka Yasuda ◽

Takeshi Yamasaki ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Study Protocol ◽

Phase Ii Trial ◽

Combined Androgen Blockade ◽

Castration Resistant ◽

Randomized Phase Ii ◽

Androgen Blockade

Repurposing Itraconazole as a Treatment for Advanced Prostate Cancer: A Noncomparative Randomized Phase II Trial in Men With Metastatic Castration‐Resistant Prostate Cancer

The Oncologist ◽

10.1634/theoncologist.2012-314 ◽

2013 ◽

Vol 18 (2) ◽

pp. 163-173 ◽

Cited By ~ 84

Author(s):

Emmanuel S. Antonarakis ◽

Elisabeth I. Heath ◽

David C. Smith ◽

Dana Rathkopf ◽

Amanda L. Blackford ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Advanced Prostate Cancer ◽

Phase Ii Trial ◽

Castration Resistant ◽

7016 POSTER Second Line Chemotherapy After Docetaxel Among Symptomatic Castration-Resistant Prostate Cancer (CPRC) Patients – GETUG-P02 Randomized Phase II Trial

European Journal of Cancer ◽

10.1016/s0959-8049(11)71967-0 ◽

2011 ◽

Vol 47 ◽

pp. S489

Author(s):

F. Joly ◽

R. Delva ◽

L. Mourey ◽

E. Bompas ◽

N. Allouache ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Second Line ◽

Second Line Chemotherapy ◽

Castration Resistant ◽

Randomized Phase Ii ◽

Line Chemotherapy

Radiolabeled anti-prostate specific membrane antigen (PSMA) monoclonal antibody J591 (177Lu-J591) for nonmetastatic castration-resistant prostate cancer (CRPC): A randomized phase II trial.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.15_suppl.tps193 ◽

2011 ◽

Vol 29 (15_suppl) ◽

pp. TPS193-TPS193

Author(s):

S. T. Tagawa ◽

N. M. Hahn ◽

D. A. Vaena ◽

D. I. Quinn ◽

W. K. Kelly ◽

...

Keyword(s):

Prostate Cancer ◽

Monoclonal Antibody ◽

Phase Ii ◽

Phase Ii Trial ◽

Prostate Specific Membrane Antigen ◽

Castration Resistant ◽

Randomized Phase Ii ◽

Specific Membrane

Olaparib combined with abiraterone in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A randomized phase II trial.

Journal of Clinical Oncology ◽

10.1200/jco.2018.36.15_suppl.5003 ◽

2018 ◽

Vol 36 (15_suppl) ◽

pp. 5003-5003 ◽

Cited By ~ 3

Author(s):

Noel Clarke ◽

Pawel J. Wiechno ◽

Boris Alekseev ◽

Nuria Sala ◽

Robert Jones ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Castration Resistant ◽

Randomized Phase II Trial of Abiraterone Alone or With Dasatinib in Men With Metastatic Castration-resistant Prostate Cancer (mCRPC)

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2019.02.010 ◽

2019 ◽

Vol 17 (4) ◽

pp. 241-247.e1 ◽

Cited By ~ 1

Author(s):

Tanya B. Dorff ◽

David I. Quinn ◽

Jacek K. Pinski ◽

Amir Goldkorn ◽

Sarmad Sadeghi ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Castration Resistant ◽

Mixed 20-peptide cancer vaccine in combination with docetaxel and dexamethasone for castration-resistant prostate cancer: a randomized phase II trial

Cancer Immunology Immunotherapy ◽

10.1007/s00262-020-02498-8 ◽

2020 ◽

Vol 69 (5) ◽

pp. 847-857

Author(s):

Masanori Noguchi ◽

Gaku Arai ◽

Shin Egawa ◽

Chikara Ohyama ◽

Seiji Naito ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Cancer Vaccine ◽

Phase Ii Trial ◽

Castration Resistant ◽

Association of Rash With Outcomes in a Randomized Phase II Trial Evaluating Cetuximab in Combination With Mitoxantrone Plus Prednisone After Docetaxel for Metastatic Castration-resistant Prostate Cancer

Clinical Genitourinary Cancer ◽

10.1016/j.clgc.2011.11.003 ◽

2012 ◽

Vol 10 (1) ◽

pp. 6-14 ◽

Cited By ~ 18

Author(s):

Mark T. Fleming ◽

Guru Sonpavde ◽

Michael Kolodziej ◽

Sanjay Awasthi ◽

Thomas E. Hutson ◽

...

Keyword(s):

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Castration Resistant ◽

Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium

Investigational New Drugs ◽

10.1007/s10637-010-9420-8 ◽

2010 ◽

Vol 29 (6) ◽

pp. 1432-1440 ◽

Cited By ~ 34

Author(s):

Deborah A. Bradley ◽

Stephanie Daignault ◽

Charles J. Ryan ◽

Robert S. DiPaola ◽

David C. Smith ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Trials ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Trial ◽

Cancer Clinical Trials ◽

Castration Resistant ◽

Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium.

Journal of Clinical Oncology ◽

10.1200/jco.2010.28.15_suppl.4684 ◽

2010 ◽

Vol 28 (15_suppl) ◽

pp. 4684-4684

Author(s):

E. J. Small ◽

T. M. Beer ◽

V. K. Weinberg ◽

C. S. Higano ◽

L. T. Nordquist ◽

...

Keyword(s):

Prostate Cancer ◽

Clinical Trials ◽

Phase Ii ◽

Phase Ii Trial ◽

Cancer Clinical Trials ◽

Castration Resistant ◽

Randomized Phase Ii ◽

Intermittent Chemotherapy